Login to Your Account

Biogen Pays Cardiokine $50M In Deal On Hyponatremia Drug

By Jim Shrine

Tuesday, July 3, 2007
Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription